The COVID-19 pandemic has led to an increase in demand for active pharmaceutical ingredients (APIs) and drugs, with several countries even banning the export of essential drugs.

GlobalData has conducted a survey to assess how the coronavirus (COVID-19) pandemic is affecting import/export and supply chain risks related to finished dose and APIs in the third quarter (Q3) of 2020, compared to the first quarter (Q1).

Analysis of the survey responses shows that an increasing number of companies are expecting only a minor risk to imports/exports. The respondents expecting just a minor risk increased from 43% in Q1 to 52% in Q3.

Finished Dose and API Risks Q1 vs Q3

Import/export and supply chain risks related to finished dose and APIs

On the other hand, the companies expecting a major risk to API and key materials imports/exports from the pandemic dropped from 35% in Q1 to 32% in Q3.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Similarly, a lesser 8% of the companies in Q3 opined that coronavirus posed a major risk to finished dose and product exports/imports, compared to 14% Q1.

The percentage of companies that anticipated no risk to imports/exports remained unchanged for both the quarters at 8%.

The analysis is based on responses received from the Pharmaceutical Trade and Supply Chain Survey between 07 July and 30 July 2020.